摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 4-ethoxyphenylglyoxylate | 80768-36-1

中文名称
——
中文别名
——
英文名称
methyl 4-ethoxyphenylglyoxylate
英文别名
Methyl 4-ethoxybenzoylformate;methyl 2-(4-ethoxyphenyl)-2-oxoacetate
methyl 4-ethoxyphenylglyoxylate化学式
CAS
80768-36-1
化学式
C11H12O4
mdl
——
分子量
208.214
InChiKey
PKRAEDHYHXDEBD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    62-63 °C
  • 沸点:
    317.6±25.0 °C(Predicted)
  • 密度:
    1.147±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    52.6
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 4-ethoxyphenylglyoxylate正丁基锂lithium diisopropyl amide 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 3.5h, 生成 methyl 2-(4-ethoxyphenyl)but-3-enoate
    参考文献:
    名称:
    Johnson, Wynona M. P.; Holan, George, Australian Journal of Chemistry, 1981, vol. 34, # 11, p. 2363 - 2368
    摘要:
    DOI:
  • 作为产物:
    描述:
    草酸二甲酯4-乙氧基苯乙酮sodium methylate 作用下, 以 甲醇 为溶剂, 反应 6.0h, 生成 methyl 4-ethoxyphenylglyoxylate
    参考文献:
    名称:
    Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents
    摘要:
    In this paper, 41 hybrid compounds containing diaryl-1,5-diazole and morpholine structures acting as dual COX-2/5-LOX inhibitors have been designed, synthesized and biologically evaluated. Most of them showed potent antiproliferative activities and COX-2/5-LOX inhibitory in vitro. Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 mu M for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 mu M vs. celecoxib: IC50 = 97.87 mu M for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 mu M) and 5-LOX (IC50 = 0.68 mu M). Meanwhile, the molecular modeling study was performed to position compound A33 into COX-2 and 5-LOX active sites to determine the probable binding models. Mechanistic studies demonstrated that compound A33 could block cell cycle in G2 phase and subsequently induced apoptosis of F10 cells. Furthermore, compound A33 could significantly inhibit tumor growth in F10-xenograft mouse model, and pharmacokinetic study of compound A33 indicated that it showed better stability in vivo. in general, compound A33 could be a promising candidate for cancer therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2019.03.008
点击查看最新优质反应信息

文献信息

  • JOHNSON, W. M. P.;HOLAN, G., AUSTRAL. J. CHEM., 1981, 34, N 11, 2363-2368
    作者:JOHNSON, W. M. P.、HOLAN, G.
    DOI:——
    日期:——
  • Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents
    作者:Zhang Li、Zhong-Chang Wang、Xin Li、Muhammad Abbas、Song-Yu Wu、Shen-Zhen Ren、Qi-Xing Liu、Yi Liu、Peng-Wen Chen、Yong-Tao Duan、Peng-Cheng Lv、Hai-Liang Zhu
    DOI:10.1016/j.ejmech.2019.03.008
    日期:2019.5
    In this paper, 41 hybrid compounds containing diaryl-1,5-diazole and morpholine structures acting as dual COX-2/5-LOX inhibitors have been designed, synthesized and biologically evaluated. Most of them showed potent antiproliferative activities and COX-2/5-LOX inhibitory in vitro. Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 mu M for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 mu M vs. celecoxib: IC50 = 97.87 mu M for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 mu M) and 5-LOX (IC50 = 0.68 mu M). Meanwhile, the molecular modeling study was performed to position compound A33 into COX-2 and 5-LOX active sites to determine the probable binding models. Mechanistic studies demonstrated that compound A33 could block cell cycle in G2 phase and subsequently induced apoptosis of F10 cells. Furthermore, compound A33 could significantly inhibit tumor growth in F10-xenograft mouse model, and pharmacokinetic study of compound A33 indicated that it showed better stability in vivo. in general, compound A33 could be a promising candidate for cancer therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.
  • Johnson, Wynona M. P.; Holan, George, Australian Journal of Chemistry, 1981, vol. 34, # 11, p. 2363 - 2368
    作者:Johnson, Wynona M. P.、Holan, George
    DOI:——
    日期:——
查看更多